These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1279 related articles for article (PubMed ID: 20414921)

  • 1. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy for melanoma: current reality and future options.
    Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
    Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Lejeune FJ; Rimoldi D; Speiser D
    Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
    Panka DJ; Atkins MB; Mier JW
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
    Strickland LR; Pal HC; Elmets CA; Afaq F
    Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
    Haluska F; Pemberton T; Ibrahim N; Kalinsky K
    Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for metastatic malignant melanoma: old drugs and new strategies.
    Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
    Lorigan P; Eisen T; Hauschild A
    Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and targeted therapy combinations in advanced melanoma.
    Flaherty KT
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.